Atorvastatin Therapy to Improve Endothelial Function in Sickle Cell Disease

NCT00072826 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

44

Enrollment

NIH

Sponsor class

Conditions

Sickle Cell Disease

Interventions

DRUG: Oxypurinol
DRUG: L-NMMA
DRUG: Acetylcholine

Sponsor

National Institutes of Health Clinical Center (CC)